Results 221 to 230 of about 3,141,404 (351)
CircZNF148 stabilizes HK1 through deubiquitinase recruitment, thereby enhancing glycolysis and lactate production. Elevated lactate promotes PD‑L1 lactylation and membrane accumulation while suppressing CD8+ T‐cell cytotoxicity, collectively facilitating immune evasion and malignant progression in TNBC.
Yuhan Jin +17 more
wiley +1 more source
The Significance of cGAS-STING Signaling in Response to Oncogenic Viruses. [PDF]
Guo L, Li L, Wang F, Liu W, Zhang Y.
europepmc +1 more source
A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu +4 more
wiley +1 more source
Mitochondrial checkpoint for interferon responses in macrophages. [PDF]
Mieland AO, Krämer OH.
europepmc +1 more source
PS.64 An Oncogenic Virus Drives Dynamic Alterations to the Tumor-Infection Microenvironment
openalex +1 more source
Small DNA tumor viruses and human cancer: Preclinical models of virus infection and disease
Megan E. Spurgeon
openalex +1 more source
IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui +12 more
wiley +1 more source
Atypical case of an orf virus infection in sheep. [PDF]
Segna A +5 more
europepmc +1 more source
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv +16 more
wiley +1 more source

